Who
Ronit Simantov
Director
Company insider
Files Form 4 as: Director, Tempest Therapeutics; Cmo & Chief Scientific Officer, Gamida Cell; Director, Clovis Oncology.
In numbers
- Trades disclosed
- 10
- Buys
- 0
- Sells
- 0
- Bought
- $0
- Sold
- $0
- Companies
- 3
- Companies where not an officer
- 2
- First trade
- 12 Jul 2021
- Last trade
- 27 Jan 2026
- Last filed
- 28 Jan 2026
Companies traded
Activity over time
Not enough dated trades to draw.
Every trade
| Traded | Company | What | Amount | |
|---|---|---|---|---|
| 27 Jan 2026filed 28 Jan 2026 | TPST Tempest Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code A | —1,230 at $0.00 | filing |
| 27 Jan 2026filed 28 Jan 2026 | TPST Tempest Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code A | —1,230 at $0.00 | filing |
| 13 Jun 2024filed 14 Jun 2024 | TPST Tempest Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code A | —16,000 at $0.00 | filing |
| 31 Jan 2024filed 2 Feb 2024 | Gamida Cell | SEC FORM 4 Code A | —480,319 at $0.00 | filing |
| 15 Jun 2023filed 20 Jun 2023 | TPST Tempest Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code A | —8,200 at $0.00 | filing |
| 8 Feb 2023filed 10 Feb 2023 | Gamida Celloption or derivative | SEC FORM 4 Code A | —116,340 at $0.00 | filing |
| 8 Feb 2023filed 10 Feb 2023 | Gamida Cell | SEC FORM 4 Code A | —58,100 at $0.00 | filing |
| 17 Jun 2022filed 22 Jun 2022 | TPST Tempest Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code A | —3,500 at $0.00 | filing |
| 6 Aug 2021filed 10 Aug 2021 | TPST Tempest Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code A | —6,635 at $0.00 | filing |
| 12 Jul 2021filed 13 Jul 2021 | Clovis Oncologyoption or derivative | SEC FORM 4 Code A | —83,212 at $0.00 | filing |
News
No headline names them, or the companies they trade most, lately.
Sectors
No trade we could place in a sector.
Related people
Nobody else traded the same names lately.